DEF: QT Imaging Holdings Seeks Shareholder Approval for Reverse Stock Split Amidst Financial Shifts and Board Elections

QT Imaging Holdings, Inc. is convening its annual stockholder meeting to vote on key proposals including the election of directors, ratification of auditors, and a proposed reverse stock split aimed at maintaining Nasdaq listing compliance, following a year of significant revenue growth but also increased net losses and cash burn.

Summary

• The Annual Meeting of Stockholders of QT Imaging Holdings, Inc. will be held virtually on August 19, 2025, at 1:00 p.m., Eastern Time.
• Key proposals for the meeting include the election of two Class I directors (Daniel Dickson and James Greene) to serve until the 2028 annual meeting, the ratification of BPM LLP as the independent registered public accounting firm for fiscal year 2025, and the approval of an amendment to the Certificate of Incorporation to effect a reverse stock split.
• The proposed reverse stock split would combine outstanding shares of Common Stock at a ratio within a range of 2:1 to 20:1, to be fixed by the Board, primarily to increase the per share price to comply with Nasdaq minimum share price requirements.
• For the fiscal year ended December 31, 2024, commercial revenue was $4.9 million, a significant increase from less than $0.1 million in 2023.
• The company shipped twelve QT Breast Acoustic CT™ Scanners in 2024, with eleven for commercial shipments and one for the NIH program, compared to no shipments in 2023.
• Gross margin for 2024 was 54%, compared to a negative margin in 2023 (comparison not meaningful due to lack of commercial revenue in 2023).
• Net loss for 2024 increased to $9.0 million, up from $6.1 million in 2023.
• Net cash used in operating activities significantly increased to $10.0 million in 2024, compared to $2.7 million in 2023.
• As of July 16, 2025, there were 28,710,144 shares of Common Stock outstanding and entitled to vote.
• The Board of Directors recommends a vote FOR all three proposals.

Sentiment

Score: 3

Explanation: While the company shows strong commercial revenue growth and increased product shipments, the significant rise in net loss and cash burn, coupled with the necessity of a reverse stock split to maintain Nasdaq listing, indicates substantial financial challenges and a precarious market position. The need for a reverse split is a strong negative signal to investors, outweighing the operational positives.

Positives

• Commercial revenue saw substantial growth, reaching $4.9 million in 2024 compared to less than $0.1 million in 2023, indicating successful market penetration.
• The company shipped twelve QT Breast Acoustic CT™ Scanners in 2024, including eleven commercial units, a significant increase from zero shipments in 2023.
• Gross margin improved to 54% in 2024, a positive shift from a negative margin in 2023, reflecting better cost management or pricing strategies as commercial operations scaled.

Negatives

• Net loss increased to $9.0 million in 2024 from $6.1 million in 2023, indicating higher operational costs or non-cash expenses despite revenue growth.
• Net cash used in operating activities significantly escalated to $10.0 million in 2024, compared to $2.7 million in 2023, highlighting increased cash burn.
• The company is proposing a reverse stock split (2:1 to 20:1) primarily to comply with Nasdaq’s minimum share price requirement, which often signals underlying stock performance issues and potential delisting risk.
• The document notes that there is no assurance the reverse stock split will result in the intended benefits, increase the market price, or maintain Nasdaq compliance, and the total market capitalization may be lower after the split.
• Directors and executive officers were delinquent in filing Section 16(a) reports for stock option grants and share distributions in 2024.

Risks

• There is no assurance that the proposed reverse stock split will result in the intended benefits, such as increasing the per share market price of the Common Stock.
• The market price of the Common Stock may not increase in proportion to the reduction in the number of shares outstanding after the reverse stock split, potentially leading to a lower total market capitalization.
• The company may not be able to meet or maintain a share price over the Nasdaq minimum average share price requirement even if the reverse stock split is effected, leading to potential delisting.
• Other factors, such as financial results, market conditions, and market perception of the business, may adversely affect the market price of the Common Stock.
• The company experienced a significant increase in net cash used in operating activities, from $2.7 million in 2023 to $10.0 million in 2024, indicating a higher burn rate that could impact liquidity.

Future Outlook

The company's primary forward-looking statement is the intent to effect a reverse stock split to increase its per share price and comply with Nasdaq's minimum share price requirement. While this aims to maintain listing, the company explicitly states there is no assurance that the split will achieve the intended benefits or that the market price will increase proportionally or be sustained. The Board reserves the right to abandon the reverse stock split if it determines it is no longer in the company's best interest.

Management Comments

• "We look forward to seeing you at the Annual Meeting." Dr. Raluca Dinu, Chief Executive Officer (from the Dear Stockholder letter)
• "The Board of Directors recommends a vote FOR Items 1, 2 and 3." Dr. Avi S. Katz, Chairman of the Board (from the Notice of Annual Meeting)

Industry Context

QT Imaging Holdings operates in the medical technology sector, specifically focusing on breast imaging with its QT Breast Acoustic CT™ Scanners. The company's recent commercial revenue growth and scanner shipments suggest increasing adoption of its technology. However, the need for a reverse stock split to maintain Nasdaq listing indicates that despite operational progress, the company faces challenges in its market valuation and capital markets standing, a common issue for smaller or early-stage MedTech companies that may require significant capital for R&D and commercialization.

Comparison to Industry Standards

• The company's significant increase in commercial revenue from less than $0.1 million to $4.9 million and the shipment of 12 scanners in 2024 (compared to none in 2023) demonstrate strong commercial traction, which is a positive indicator for a MedTech company in its early commercialization phase.
• However, the simultaneous increase in net loss from $6.1 million to $9.0 million and a substantial rise in net cash used in operating activities from $2.7 million to $10.0 million suggest that the company's growth is currently highly capital-intensive and not yet profitable, which is not uncommon for MedTech startups but indicates a high burn rate.
• The proposal for a reverse stock split to meet Nasdaq minimum share price requirements is a common measure taken by companies whose stock price has fallen below exchange thresholds. While it addresses a listing compliance issue, it is generally viewed as a negative signal by the market, as it often reflects a lack of investor confidence or sustained financial underperformance relative to established industry players like Hologic, Inc. (mammography systems) or Siemens Healthineers (imaging solutions), which typically maintain stable or growing stock prices without such interventions.
• The company's gross margin of 54% in 2024, while an improvement from negative, is a reasonable starting point for a medical device company, though it would ideally need to improve further to achieve profitability, especially when compared to mature medical device companies that often boast higher gross margins due to economies of scale and established product lines.

Management Changes

Corporate Governance

Related Party Transactions

• **Working Capital Notes with GigAcquisitions5:** GigCapital5 issued an Eleventh Amended and Restated Working Capital Note for $1,500,000 to GigAcquisitions5. $943,640 was partially converted into 94,364 shares of common stock and 94,364 private warrants, and the remaining $556,360 was repaid.
• **Non-Convertible Working Capital Note with GigAcquisitions5:** An unsecured loan of $66,360 was made by GigAcquisitions5, later amended and restated to $262,247, to provide additional working capital.
• **Extension Note with GigAcquisitions5:** An Eleventh Amended and Restated Promissory Note for $1,560,000 was issued to GigAcquisitions5, with its maturity date extended to March 4, 2025. On November 22, 2024, this note was exchanged for shares and warrants of the company in a private placement.
• **Notes with Dr. John Klock:** The 2022 Klock Note for $2,643,725 and the QTI Working Capital Note for $705,000 (aggregate principal as of Sep 30, 2023) were assumed by the company. Their maturity dates were extended to July 1, 2025, and then further extended to October 21, 2027, on February 26, 2025.
• **Data Use and License Agreement with QT Imaging Center (Dr. Klock's former practice):** Entered into on April 3, 2024, granting the company a license to use de-identified health information for research and commercialization of its products.
• **Services Agreement with QT Imaging Center:** Entered into on April 5, 2024 (effective April 1, 2024), for the Practice to provide healthcare services, clinical trial assistance, R&D support, and training. Dr. Klock was compensated at $450 per hour for a minimum of 15 hours/week, not exceeding 60 hours/month. This agreement terminated on December 31, 2024, due to Dr. Klock's retirement.
• **Space and Equipment Sublease with QT Imaging Center:** Entered into on April 17, 2024, for the Practice to sublease medical equipment and space from the company. This agreement terminated on December 31, 2024, due to Dr. Klock's retirement.
• **Sublease Agreement with the Practice (Dr. Klock):** Entered into on January 23, 2025, for the Practice (now continued by Dr. Klock post-retirement) to sublease the same space. Rent is $5,666.00/month until May 31, 2025, increasing thereafter, and the agreement expires upon termination of the Prime Lease in April 2027.

Stakeholder Impact

• **Shareholders:** Will vote on key corporate governance matters, including director elections and the reverse stock split. The reverse stock split will reduce the number of outstanding shares and could impact share price, potentially affecting liquidity and market perception. Fractional shares will be rounded up, which is beneficial for small holders. The potential for delisting from Nasdaq if the reverse split is unsuccessful poses a significant risk.
• **Employees:** Executive compensation plans are in place, including base salaries, annual bonuses tied to financial metrics (total revenue and cash balance), and equity-based awards designed for long-term retention and performance alignment. The company maintains various employee benefit plans.
• **Customers:** The continued operation of the QT Imaging Center (now under a sublease with Dr. Klock's continued practice) suggests ongoing access to services and training related to the company's breast imaging technology.
• **Creditors:** Existing notes from GigAcquisitions5 and Dr. John Klock have been managed through conversions, repayments, and maturity extensions, indicating ongoing financial arrangements with key creditors.
• **Management:** Executive officers' compensation is tied to company performance, and their equity awards are subject to vesting schedules and change-in-control provisions. The board and its committees provide oversight and guidance.

Next Steps

• The Annual Meeting of Stockholders will be held on August 19, 2025, to vote on director elections, auditor ratification, and the reverse stock split proposal.
• If approved, the reverse stock split would become effective upon filing the Amendment to the Charter with the Secretary of State of Delaware, with exact timing determined by the Board.
• Final voting results from the Annual Meeting will be reported on a Form 8-K filed with the U.S. Securities and Exchange Commission.
• Stockholders wishing to submit proposals for the 2026 proxy statement must do so by April 21, 2026, or within specified alternative deadlines if the meeting date changes.
• Stockholders intending to present director nominations or other proposals at the 2026 annual meeting must comply with advance notice provisions in the Bylaws, generally between April 21, 2026, and May 21, 2026.

Key Dates

Recommendation

Keywords

QT Imaging Holdings, Reverse Stock Split, Nasdaq Compliance, SEC Filing, Proxy Statement, Annual Meeting, Financial Results, Net Loss, Commercial Revenue, Cash Burn, Corporate Governance, Executive Compensation, Medical Imaging, Breast Imaging, QT Breast Acoustic CT